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Abstract
Background: A large number of human inherited and acquired diseases and phenotypes are caused by mutations
in G protein-coupled receptors (GPCR). Genome-wide association studies (GWAS) have shown that variations in the
ADGRD1 (GPR133) locus are linked with differences in metabolism, human height and heart frequency. ADGRD1 is a
Gs protein-coupled receptor belonging to the class of adhesion GPCRs.
Results: Analysis of more than 1000 sequenced human genomes revealed approximately 9000 single nucleotide
polymorphisms (SNPs) in the human ADGRD1 as listed in public data bases. Approximately 2.4 % of these SNPs are
located in exons resulting in 129 non-synonymous SNPs (nsSNPs) at 119 positions of ADGRD1. However, the
functional relevance of those variants is unknown. In-depth characterization of these amino acid changes revealed
several nsSNPs (A448D, Q600stop, C632fs [frame shift], A761E, N795K) causing full or partial loss of receptor function,
while one nsSNP (F383S) significantly increased basal activity of ADGRD1.
Conclusion: Our results show that a broad spectrum of functionally relevant ADGRD1 variants is present in the
human population which may cause clinically relevant phenotypes, while being compatible with life when
heterozygous.
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Background
More than three dozen human inherited and acquired
diseases are caused by mutations in G protein-coupled
receptors (GPCRs) [1–4]. At the molecular level, muta-
tional alteration in GPCRs can have two major conse-
quences – the gain and loss of receptor function. Most
mutations causative for human diseases have been found
in rhodopsin-like GPCRs, which comprise the largest
family of GPCRs, but only a few mutations in the second
largest family; the adhesion GPCRs (aGPCRs). Examples
are ADGRG1 (GPR56) and ADGRV1 (VLGR1), where
gene mutations cause brain malformation (bilateral fron-
toparietal polymicrogyria) [5] and a form of Usher syn-
drome [6], respectively.
ADGRD1, a member of the aGPCR family, was among
the first aGPCRs identified in genome-wide association
studies (GWAS) where SNPs in intronic regions were as-
sociated with human height in Sorbs and Korean popula-
tions [7, 8]. A GWAS with over 1000 subjects revealed an
association of ADGRD1 with the postprandial levels of
very low density lipoproteins (VLDL) [9]. Marroni et al.
found two SNPs associated with RR duration leading to
an increase of one beat per second in heart rate [10].
Recently, the methylation status of the ADGRD1 locus
was associated with body weight in humans [11] which is
in agreement with an earlier study connecting SNPs in
this gene and body weight in mice [12].
Our data base analysis of more than 1000 sequenced
human genomes including the 1000 Genomes [13],
exome sequencing projects (NHLBI-ESP [14], ClinSeq
Project [15]) and the human haplotype map [16], revealed
approximately 9000 single nucleotide polymorphisms
(SNPs) in the human ADGRD1 gene. Out of those 2.4 %
SNPs are located in exons leading to 129 amino acid
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changes at 119 positions (Fig. 1a). Compared to other
GPCR genes [17] the number of SNPs in ADGRD1 is not
significantly different. However, a functional relevance of
most SNPs can only be evaluated by experimental testing.
In general, their large size, the lack of agonists and know-
ledge about their signal transduction, until recently,
rendered the functional characterization of aGPCRs very
difficult.
ADGRD1, like most members of the aGPCR family, dis-
plays a characteristically complex and long N terminus.
The ectodomain contains a pentraxin-like (PTX) domain
(as a part of the Laminin G3 domain (LamG3)) as well as
a GPCR autoproteolysis inducing (GAIN) domain. The
structure of the GAIN domain, which also harbors the
GPCR proteolysis site (GPS), has been resolved [18],
showing that it is divided into two subdomains: the
up to six α-helices containing subdomain A and the
13 β-strands containing subdomain B. A proposed
autoproteolytic event at the GPS [19] cleaves the full
length receptor protein in an extracellular N-terminal
fragment (NTF) and an intracellular C-terminal frag-
ment (CTF), which contains the seven transmembrane
region [20, 21].
We have recently shown that ADGRD1 couples to the
Gs protein/adenylyl cyclase signaling pathway [22] and is
activated by a tethered agonist [23]. This now allows for
characterization of natural ADGRD1 variants found in
the human population. We identified several inactivating
and constitutively activating mutations in the human
ADGRD1 gene. This will provide the molecular basis of
understanding phenotypes related to ADGRD1 variants
and will initiate in-depth clinical characterization of
individuals carrying such receptor variants.
Results and discussion
Allelic variation is comparable to rhodopsin-like GPCR
and variations can occur in all parts of ADGRD1
According to NCBI database of Single Nucleotide
Polymorphisms (dbSNP) nearly 9000 single nucleotide
polymorphisms were identified in the ADGRD1 gene
(ADGRD1, Gene ID: 283383, chromosomal position
[GRCh38 Primary Assembly, human Chr 12, NT_
029419.13] 130953907..131141465) [24]. Approximately
96 % of SNPs are intronic, while the remaining 4 % clus-
ter in untranslated regions (UTR) and exons. The SNPs
within exons led to 88 synonymous changes and 129
Fig. 1 nsSNPs in ADGRD1 influence cell surface expression and cAMP responsive element activity. a Schematic amino acid structure of ADGRD1
which consists of 874 amino acids. The signal peptide (SP) is followed by a pentraxin domain (PTX), the GPCR autoproteolysis inducing (GAIN)
domain (including the two subdomains) harboring a GPCR proteolysis site (GPS), the 7TM region (I-VII) with 3 intra and 3 extracellular loops and a
C-terminal tail (CT). The receptor is divided into two fragments: an N-terminal fragment (NTF) and a C-terminal fragment (CTF) after autoproteolytic
cleavage at the GPS. Each vertical line indicates a position influenced by amino acid changing single nucleotide variants (data collection: 21-04-2015).
b Each dot represents the mean of one inspected nsSNPs in ADGRD1 (for details see Additional file 1). The dotted lines indicate the one- and twofold
standard deviation (SD) from wt in CRE-SeAP activity. Data are given as % of wt activity and cell surface expression as mean ± SD. Empty vector (EV)
served as negative control (basal activity: EV: 568,311 ± 59,100 counts; wt: 786,125 ± 85,787 counts; n = 4; basal expression: EV: 0.01 ± 0.02 OD492 nm;
wt: 0.70 ± 0.11 OD492 nm; n = 12)
Fischer et al. BMC Genomics  (2016) 17:609 Page 2 of 9
non-synonymous exchanges including 3 frameshifts and
1 stop mutation (Table 1). Additional file 1: Table S1
summarizes characteristics and origin of 109 nsSNPs
that were analyzed in this study. ADGRD1 displays a
SNP frequency of ~24.8/100 codons, which is comparable
to those of rhodopsin-like GPCRs (Table 1) [17]. Notably,
there is no ‘hotspot’ of nsSNPs within the coding region
(Fig. 1a). One should consider that sequencing errors
might be responsible for some of the listed nsSNPs and
that all functionally relevant mutations occurred only
heterozygously at low frequency in the populations inves-
tigated. However, reevaluation of sequencing data of some
inactivation mutations revealed considerable coverage of
the detected nsSNPs in those individuals (personal com-
munication Dr. Biesecker), thereby verifying some of the
most striking variants.
nsSNPs in ADGRD1 change receptor activity on a broad
scale
Receptor function can be evaluated at the levels of
signaling activity and of membrane expression, latter as
a measure of proper folding and translocation. For ex-
ample, most of the loss-of-function mutations in the
vasopressin type 2 receptor, which lead to nephrogenic
diabetes insipidus, display significant reduction of cell
surface expression [25]. Gain-of-function GPCR mutants
exhibit mostly lower cell surface levels as a result of re-
duced phosphorylation, structural instability and enhanced
internalization and degradation but show simultaneously
significant increases in basal signaling activity [4, 26–28].
ADGRD1 is a Gs protein-coupled receptor with high
basal activity and high expression levels at the cell sur-
face [22, 23, 29]. To efficiently evaluate the functional
relevance of the natural occurring nsSNPs we initially
took advantage of the high basal activity of ADGRD1 as
a sensitive measure for its Gs-protein coupling ability.
Thus, we examined 109 nsSNPs in an assay that uses
cAMP response element (CRE) to trigger the secretion
of an alkaline phosphatase (CRE-SeAP assay) to assess
signaling activity, while cell surface and whole cell ex-
pression was monitored in parallel through ELISAs
(Additional file 2). Supported by experiences with other
GPCRs [1–4] we considered the combination of these
assays to be sufficient to identify most mutants with
impaired or significantly increased basal activity and/or
altered cell surface trafficking. Based on the function
(basal CRE levels) and expression levels of the human wt
ADGRD1 a twofold standard deviation (SD) was set as
arbitrary threshold to define “normal” function. This is a
reasonable range as shown in studies evaluating the
functional distribution of GPCR orthologs [30, 31].
Except for two nsSNPs (M1T, N795K), all examined
nsSNPs displayed very similar total cell expression levels
compared to wt ADGRD1 (Additional file 2). To identify
those nsSNPs, which cause alteration of basal CRE-level
and/or of cell surface expression, all variants were plot-
ted in respect to these parameters (Fig. 1b). Almost 60 %
of the analyzed receptor mutants exhibited wt CRE-
SeAP levels, 12.5 % showed more than and 11.6 % less
than 2-fold SD different CRE-response from wt (Fig. 1b;
Additional file 2). The remaining variants were within
the 1-fold SD. With 80 % of the variants displaying wt
cell surface expression levels this parameter was less
effected (Fig. 1b; Additional file 2). Activity-altering
nsSNPs were found evenly distributed throughout the
receptor (Table 2).
nsSNPs within ADGRD1 change basal activity levels in a
domain-specific manner
The majority of nsSNPs in the N terminus that alter
receptor activity levels were located either at the very N
terminus or within the GAIN domain (Fig. 2a). The very
N terminus includes the signal peptide, a PTX-like
domain (as a part of the LamG3 domain) and a 112
amino acid-long spacer region. In this receptor region,
nsSNPs mainly affected the receptor expression level
with a subsequent decrease in CRE activity levels. M1T
(rs144264048, T > C) was found heterozygously in a
European American population (Additional file 1). Inter-
estingly, this missense mutation was expressed in whole
cell and can be detected at low levels at the cell mem-
brane. However, relevant basal CRE activity was not
observed (Fig. 2a). These findings are in accordance with
a report by Kozak, who found that a one-base change of
Table 1 Comparison of exon SNPs of human ADRGD1 with
Rhodopsin-like GPCRs
Human ADGRD1 a Rhodopsin-like GPCRs
(Stäubert et al., 2014 [17])
Absolute n n/100 codons n/100 codons
Synonymous 88 10 10
Non-synonymous 129 15 15
Frameshift 3 0.3 0.3
Stop mutation 1 0.1 0.5
a Data collection: 21.04.2015
Table 2 Domain distribution of functional relevant nsSNPs
AA Inspected nsSNPs ±2SD
n n n (% inspected nsSNPs)
Whole receptor 874 107 23 (21.5)
N terminus 570 76 17 (22.4)
PTX 111 15 3 (20.0)
GAIN 295 43 9 (20.9)
7TM 243 21 4 (19.0)
C terminus 61 10 2 (20.0)
Exclusion of stop and frameshift mutants
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AUG can function as initiator codon [32]. The efficiency
for initiation of ACG, however, is under 3 % compared
to AUG [32]. There have been reports of an existing
AUG-ACG mutation in the human α globulin gene,
which reduces gene expression resulting in clinical thal-
assemia [33].
Two mutations, E78K [rs267603378, G > A] and
G141D [rs142759046, G > A], in the spacer region, led
to significant increase in activity, which cannot be ex-
plained by an associated elevated membrane expression
(Fig. 2a). E78K was identified by Y. Samuels (NHGRI/NIH;
http://www.ncbi.nlm.nih.gov/clinvar/RCV000062447/) as
one out of three nsSNPs within ADGRD1 that are found in
malignant melanoma tissue [34]. G141D was found in two
heterozygous genotypes out of 2201 in African Americans
by NHLBI ESP and by 1000 Genomes (Additional file 1).
There were two mutations, Y85C [rs199848650, A > G]
and F110L [rs148928637, C > G], in the spacer region
that led to significant decrease in activity (Fig. 2a). Y85C
appeared in the ClinSeq study that analyzed 1306
chromosomes from 662 people of a European popula-
tion. Of note, ClinSeq includes healthy and disease-
Fig. 2 nsSNPs in ADGRD1 influence signaling activity in compartment-depending manner. a N-terminal nsSNPs of ADGRD1 have different
influences on signaling activity and expression. The positions of nsSNPs within the N-terminal fragment (NTF) are indexed through the pictogram
under the graph. b nsSNPs in 7TM core and C terminus influence cAMP response element (CRE)-signaling activity. The schema under the graph
indicates the position of signaling activity relevant nsSNPs: S667L in intracellular loop (ICL) 2, V764M in TM6 (VI), N795K in TM7 (VII) and A816T
and T827M in C terminus. c Constitutive activity of P2Y12-CTF-mutant is lost after insertion of N795K. (A-C) Graphs show the percentage of
wildtype (wt) after normalization to mock control of functional relevant nsSNPs in CRE-SeAP activity (EV: 568,311 ± 59,100 counts; wt: 786,125 ± 85,787
counts; n = 4), cell surface expression (EV: 0.02 ± 0.03 OD492 nm; wt: 0.70 ± 0.11 OD492 nm; n = 9) and whole cell expression (EV: 0.08 ± 0.07 OD492nm;
wt: 0.97 ± 0.16 OD492nm; n = 7). To compare differences of receptor mutants to wt basal activity or expression levels an unpaired two-tailed t-test was
performed with * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. d Activation analysis of nsSNPs upon stimulation with the tethered agonist-derived peptide p13.
After normalization to mock control (EV: 872 ± 200 counts; n = 7) data are shown as percentage of wildtype stimulated with p13 (wt + p13: 5.3 ± 1.3
x-fold over EV; n = 7). To analyze significance of receptor mutant activation after p13 stimulation a two-way ANOVA with Bonferroni as post-test was
used: * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001. a-d Data are given as means ± SD
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affected participants and had an initial focus on cardio-
vascular disease [15]. Yet, the individual carrying this
SNP showed no obvious clinical phenotype (personal
communication Dr. Biesecker).
W174S (rs141606054, G > C), E178K (rs148148477,
G > A) and G195R (rs267603379, G > A) are located
within two alpha helical structures of the PTX-like do-
main, as predicted via hydrophobicity plot according to
Kyte- Doolittle with Protean 7.1.0 (DNAStar, Lasergene).
The latter two SNPs have also been identified by
Samuels’ laboratory (NHGRI/NIH) as being found in
samples from malignant melanoma. Amino acid changes
at these positions significantly decrease cell surface
expression, which results in an even more pronounced
reduction of CRE levels (Fig. 2a). W174 and G195 are
100 % conserved in 74 vertebrate ADGRD1 orthologs
whereas the position E178 is substituted by aspartate
in 12 % of orthologous sequences but not by lysine
(Additional file 2).
The GAIN domain is considered an important struc-
tural and functional element of aGPCRs [18]. Nine out
of 43 inspected nsSNPs within the GAIN domain change
ADGRD1-mediated CRE levels, the majority of them
leading to constitutive activation of the receptor (Fig. 2a).
This is most pronounced in case of F383S (rs200232576,
T > C), which increased receptor activity by 262 %. Con-
sidering that ADGRD1 has been associated with changes
in heart frequency [10] it is striking to see that the most
prominent activity increasing SNP origins from a cohort
that includes participants with potential heart maladies.
Nonetheless, F383S is found in a single person of the
ClinSeq project [15] that does not show signs of coronary
artery disease (personal communication Dr. Biesecker).
The position F383 is conserved and only substituted by
tyrosine in orthologs (Additional file 2). Within the GAIN
domain only A448D (rs200173874, C > A) reduced
receptor activity most likely because of reduced plasma
membrane expression. This functional relevance of A448
is in agreement with its high evolutionary conservation
(Additional file 2). Interestingly, out of the six investigated
nsSNPs within the highly conserved GPS region, there
was none that significantly changed receptor activity.
Several nsSNPs within the highly conserved 7TM core
(S667L (rs377401276, C > T) in ICL2, A761E (rs369201469
C >A) and V764M (rs149434203, G >A) in TM6 and
N795K (rs369853823, C > A) in TM7) led to a reduction in
receptor-function (Fig. 2b). N795K completely abolished
the CRE receptor signal. Even introduced into the consti-
tutive active P2Y12-CTF chimera [23], N795K completely
abolished the function of this construct (Fig. 2c). N795K
was found to be heterozygous in European Americans
(NHLBI ESP) with a minor allele frequency of 0.000077
(Additional file 1). The position is highly conserved in
vertebrates (Additional file 2).
The importance of cleavage for aGPCR function is still
a matter of debate, yet GPR133-cleavage deficient mu-
tants have been shown to display similar cell surface and
cAMP levels compared to the wt receptor [22]. In line
with this, a selection of activating, inactivating and con-
trol SNPs with wt function throughout the GPR133
structure did not display any changes in occurrence of
cleavage (Additional file 2).
Our analysis includes data from three studies with a
pathophysiological focus: (1) coronary artery disease
(ClinSeq study; [15]), (2) malignant melanoma [34] and
(3) heart, lung and blood disorders (the NHLBI-ESP
study; [14]). So far, for none of the functionally altered
variants a direct attribution to an affected individual
could be found. However, two nsSNPs, with significantly
reduced, and one nsSNP, with increased signaling abil-
ities, were found in samples with malignant melanoma.
Since all variants were found in adults our data indi-
cate that inactivation or constitutive activation of only
one ADGRD1 allele is compatible with life and does not
result in a clinically relevant phenotype in humans.
However, association of nsSNPs in ADGRD1 with com-
mon human diseases cannot be excluded. Of note, the
nsSNP A446V, which was previously identified by a
study searching for genes influencing human height [8]
displayed wt function in our assays.
Application of the Stachel-derived peptide agonist p13
can restore wt activity levels of selected nsSNPs
To evaluate the capability of these receptor variants to
be activated through the tethered peptide agonist of
ADGRD1, we stimulated selected receptor mutants with
500 μM of the synthetic peptide agonist p13 [23]
(Fig. 2d). As a functional read-out a luciferase based
reporter gene assay under the control of CREB was used.
Half of the analyzed nsSNPs showed wt-equivalent acti-
vation levels upon peptide application despite reduced
basal activity levels, indicating that these mutants are
capable of exerting wt function. Some nsSNPs with sig-
nificantly reduced activation levels through p13 (A448D,
V764M, N795K and A816T) were expressed at lower
levels in the cell membrane, accounting for the observed
lack in stimulation (Fig. 2a and d). However, there are
also nsSNPs (F110L, W174S, E178K, G195R) which
showed significantly reduced cell surface expressions but
wt typical peptide responses (Fig. 2a and d). It seems
that peptide stimulation can compensate lack of mem-
brane expression as long as the mutation is within the
very N-terminal region of the receptor. Of note, all
nsSNPs that do not reach wt activation levels upon p13
are located either in the GAIN domain or the 7TM core.
It is conceivable from this data that there are natural
variations within the binding pocket of the tethered
agonist, which is yet to be defined. Specifically, position
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A761 in TM6 seems to be an interesting candidate since
the reduction in cell surface expression is not low
enough to explain the deficiency in activation through
p13 (Fig. 2b and d). N795K, as part of TM7 most likely
disrupts proper protein folding as plasma membrane ex-
pression is severely disrupted. Therefore, neither basal nor
peptide-induced activity was detected (Fig. 2c and d).
The constitutively active F383S-mutant, as a part of
the second β-strand in subdomain B of the GAIN
domain [18], exhibited an even more pronounced p13-
induced activation (Fig. 2d). Here additive effects are
likely the cause.
Characterization of ORF-disrupting ADGRD1 variants
The natural variant Q600stop (rs200986302, C > T) leads
to a premature truncation of ADGRD1 in the first intra-
cellular loop (Fig. 3a). Nonetheless, the protein was
expressed at cell surface ELISA (Fig. 3b). As expected,
truncation of the last six transmembranes resulted in a
complete lack of basal and peptide-induced signal trans-
duction (Fig. 3c). This unusual SNP was also found het-
erozygously in a single person in the ClinSeq study. Again
no clear sign of coronary artery disease was evident
(personal communication Dr. Biesecker).
There is a natural variation of ADGRD1 that causes an
extension of the reading frame (Fig. 3a). In C632fs
[rs34176886, />C]), an insertion of one base pair in
extracellular loop one leads to a frameshift which results
in a 78-amino acid longer receptor. Even though it
seems that this protein is produced in the cell, it lacks
expression in the plasma membrane. Therefore, no sec-
ond messenger activity was detected (Fig. 3b). To verify
the frameshift, the Flag epitope was set into frame of this
mutant right upstream of the newly gained stop codon.
A pronounced signal in the sandwich ELISA indicated
the translation of this frameshift-caused artificial protein
(Fig. 3b).
In sum, there are at least two naturally occurring
nsSNPs that lead to non-functional ADGRD1 due to
gross alteration of the receptor protein chain. In contrast
to classical rhodopsin-like GPCR, where truncation after
the first transmembrane domain would be considered
dysfunctional, aGPCRs are thought to have bimodal
functions [35–37]. Here, the CTF mediates the intracel-
lular signal cascade, called ‘cis-signaling’ while the NTF
resolves the ‘trans-signaling’ to other cells. Since there is
no report on ADGRD1-deficient animal models available
the individual functions and the physiological relevance
of NTF vs. CTF are unknown yet.
Conclusion
Our analysis of naturally occurring SNPs within the
ADGRD1 gene showed that this receptor displays muta-
tion frequencies that are similar to a prototypic GPCR.
While functional consequences of the nsSNPs with re-
spect to intracellular signal transduction are highly vari-
able, cleavage does not seem to be affected. It seems that
a range between complete abolishment of up to a 3-fold
Fig. 3 nsSNPs leading to length variations do not elicit intracellular signal transduction. a Schematic structure of the cloned constructs for the
length variation Q600stop and the frameshift C632fs are shown in the middle. The signal peptide (dark grey triangle) is followed by an HA-tag
(light grey box) and the functional domains of the NTF: a PTX (grey box labeled ‘PTX’) and GAIN domain (rectangle including GPS as circle).
Transmembrane units are indicated as grey boxes downstream the GPS circle. The C terminus features a hexagonal FLAG-tag. The star indicates
the newly cloned 3′UTR region. b Two days after transfection CRE-SeAP assay, cell surface and whole cell ELISA were performed. Graphs show the
percentage of wildtype (wt) after normalization to mock control of functional relevant nsSNPs in CRE-SeAP activity (EV: 568,311 ± 59,100 counts;
wt: 786,125 ± 85,787 counts; n = 4), cell surface expression (EV: 0.02 ± 0.03 OD492 nm; wt: 0.70 ± 0.11 OD492nm; n = 9) and whole cell expression
(EV: 0.08 ± 0.07 OD492 nm; wt: 0.97 ± 0.16 OD492 nm; n = 7). c Stimulation with p13 could not activate Q600stop. Data are shown as x-fold over mock
control (EV: CREB-Luciferase: 1320.6 ± 628.1 counts; n = 4). a-c Data are given as means ± SD. To compare differences of receptor mutants to
wildtype basal activity or expression levels an unpaired two-tailed t-test was performed, for receptor activation after p13 stimulation two-way
ANOVA with Bonferroni as post-test was used, ** p ≤ 0.01 *** p≤ 0.001; n.d., not detectable
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increase in ADGRD1 function is compatible with human
life and development at least with only one allele being
affected. Gene-deficient animal models will shed light on
the physiologic relevance of this evolutionarily conserved
GPCR. However, the existence of clinically healthy
carriers for functionally relevant ADGRD1 variants
will eventually lead to the identification of homozygous /
compound heterozygous individuals exposing the pheno-
typic relevance also in humans.
Methods
If not stated otherwise, all standard substances were
purchased from Sigma-Aldrich (Taufkirchen, Germany),
Merck (Darmstadt, Germany), and C. Roth GmbH
(Karlsruhe, Germany). Cell culture material and primers
were obtained from Thermo Fisher Scientific Inc.,
(Darmstadt, Germany).
Data base search for single nucleotide polymorphisms
Non-synonymous SNPs (nsSNPs) found in human
ADGRD1 were extracted (latest update 21-04-2015)
from the NCBI database of Single Nucleotide Poly-
morphisms (dbSNP) [24], which combines results from
1000Genomes [13], exome sequencing projects (NHLBI-
ESP [14], ClinSeq Project [15]), the human haplotype
map (HAP-Map [16]) as well as smaller sequencing
projects (e.g. exome, Illumina Chip). A novel nsSNP
(A446V) was found by an exome sequencing study
which identified alterations influencing human height
[8] and was also included.
Generation of wild type (wt) and mutant ADGRD1
constructs
The human ADGRD1 was N-terminally tagged with a
haemagglutinin (HA) epitope and C-terminally tagged
with a FLAG epitope based on [22]. nsSNPs were gener-
ated through site-directed mutagenesis strategy. One of
the reported nsSNPs results in a frameshift and prolongs
the protein by 78 amino acids (AA). To generate this
frameshift mutant (C632fs), it was necessary to clone the
ADGRD1 mRNA 3′UTR region (NM_198827.3) from
human leucocytes (primer: forward 5′-GTACATGTTT
GCCACGCTCA-3′, reverse 5′-GATGAAGGGAGGCT
CAAGGG-3′) and insert a Flag tag into the new frame
in front of the new stop codon to evaluate its expression
levels. One of the nsSNPs, (Q600stop), results in a
premature stop codon central of the intracellular loop 1
(ICL1). To generate this mutant it was necessary to
clone the FLAG-epitope upstream of the stop signal
(primer: forward 5′-tacaaggatgacgacgataagTAGCGCT
ACCACATCCACG-3′, reverse 5′-gtcgtcatccttgtaatcGT
TCCGGATGGTGCTCAC-3′, small letters indicate the
FLAG sequence).
All plasmids were introduced into the eukaryotic
expression vector pcDps. All generated constructs were
confirmed by sequencing.
Cell culture and transfection
COS-7 and HEK293T cells were cultured in Dulbecco’s
minimum essential medium (DMEM) containing 10 %
fetal bovine serum (FBS), 100 units/ml penicillin and
100 μg/ml streptomycin at 37 °C and 5 % CO2 in a hu-
midified atmosphere. One day prior to transfection,
COS-7 cells were split into 48-well plates (3 × 104 cells/
well for cell surface ELISA), or 6-well plates (3 × 105
cells/well for sandwich ELISA and Western Blot). For se-
creted alkaline phosphatase (SeAP) and luciferase assays
HEK293T cells were split into 96-well plates (3 × 104
cells/well). Transfection of cells was done using Lipofec-
tamine™ 2000 (Thermo Fisher Scientific Inc.,, Darmstadt,
Germany) according to the manufacture’s protocol.
Functional assays
Because ADGRD1 is a Gs-coupled receptor function was
measured with cAMP response element (CRE) secreted
alkaline phosphatase (SeAP) and CRE binding protein
(CREB) luciferase assays. SeAP plasmid (Takara Bio Europe
SAS, Saint-Germain-en-Laye, France) and wt or mutant
ADGRD1 constructs were co-transfected with each 75 ng
of DNA/well. Basal and peptide agonist induced luciferase
as well as SeAP levels were measured after 5 h of incuba-
tion. For SeAP experiments endogenously expressed alka-
line phosphatases were heat inactivated for 2 h right before
the measurement. 10 μM forskolin was used as positive
control for CRE and CREB activities. As an additional read-
out for cAMP formation we measured luciferase activity
under the control of CREB. Thus, co-transfection of 50 ng
receptor plasmid and 50 ng luciferase plasmid (PathDetect
trans-reporting System) was performed using HEK293T
cells. Luciferase activity was detected using steadylite plus
(PerkinElmer, Rodgau, Germany).
Expression
To detect cell surface and whole cell expression in
transfected COS-7 cells ELISAs were used as described
previously [38].
Data analysis
Measurements were performed at least three times in
triplicates. After normalization to mock-transfection
(empty vector (EV)) data were compared to wt function
and expression in percentage of each trial. All amino
acid positions are based on wt ADGRD1 variant
NP_942122.2. Graphical and statistical analyses were
done using Prism version 5.01 (GraphPad Software Inc.,
San Diego, CA). Statistical methods are described in the
figure legends.
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